NTRA stock forecast, quote, news & analysis
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology... Show more
Why Natera (NTRA) Stock Is Up +21.8% in the Last 30 Days
Key Takeaways
- Natera (NTRA) shares rose approximately 21.8% over the last 30 days, climbing from a close near $338.70 to about $412.56 and reaching an all-time high.
- The advance was driven by strong Q2 2026 results, raised full-year revenue guidance, and a series of regulatory milestones for its Signatera oncology test.
- Signatera received Japanese regulatory approval as a companion diagnostic in muscle-invasive bladder cancer, extending earlier clearances in colorectal cancer and the U.S.
- Several Wall Street firms raised price targets or initiated coverage with bullish ratings, reinforcing positive sentiment.
- Longer-term momentum remains tied to molecular residual disease (MRD) volume growth, reimbursement expansion, and international commercialization.
Natera (NTRA) Company Overview and Market Position
Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) and genetic testing across three core areas: oncology, women's health, and organ health. Its technology platform combines molecular biology techniques with bioinformatics and artificial intelligence to deliver non-invasive tests. Key products include Signatera, a tumor-informed assay for detecting molecular residual disease and monitoring cancer recurrence; Panorama, a non-invasive prenatal test; and Prospera, an assessment used in organ transplant rejection.
Natera holds a leading position in the rapidly growing MRD testing market, where Signatera is used to guide treatment decisions and monitor patients after surgery. Investors follow the stock closely because of its exposure to personalized medicine, its expanding regulatory approvals, and its potential for sustained high-growth revenue as reimbursement coverage broadens.
Natera (NTRA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NTRA climbed roughly 21.8%, advancing from a closing level near $338.70 to approximately $412.56. The rally accelerated in mid-to-late September, with the stock breaking into record territory as oncology momentum and analyst upgrades compounded.
The quarterly trend has been similarly powerful. Since late July, when shares traded near $262, NTRA has surged by more than 55% as the market re-rated the company following a stronger-than-expected earnings report and a sequence of regulatory wins. The move reflects a sustained multi-month uptrend rather than a single-event spike, supported by record test volumes and improving average selling prices.
What Drove NTRA Stock Price in the Last 30 Days
The primary catalyst was a September approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) clearing Signatera as a companion diagnostic in muscle-invasive bladder cancer. The clearance enables Signatera to help identify patients who may benefit from adjuvant immunotherapy, with a commercial launch in Japan targeted for the first half of 2027. The news followed a June PMDA clearance for colorectal cancer and an earlier U.S. FDA approval, positioning Signatera as a first mover in MRD companion diagnostics.
Investor sentiment was further supported by analyst activity. RBC raised its price target to $460 from $350 while maintaining an Outperform rating, and UBS lifted its target to $435 from $290. Rothschild & Co Redburn initiated coverage with a Buy rating and a $385 target, citing Natera's leadership in molecular residual disease testing.
These developments built on second-quarter results reported in early August, when revenue rose about 38% year over year to roughly $753 million, clinical MRD volumes increased 56%, and management raised full-year 2026 revenue guidance by $100 million at the midpoint to a range of $2.85 billion to $2.91 billion.
What Drove NTRA Stock Performance Over the Last Quarter
The broader quarterly advance has been anchored by accelerating fundamentals and expanding regulatory validation. Record MRD volumes, including the largest sequential increase in company history, demonstrated growing physician adoption of Signatera. Signatera's average selling price rose to roughly $1,275, with management reiterating a longer-term target near $2,000 as Medicare and commercial reimbursement coverage expands.
On the regulatory front, Natera achieved several firsts during the period: the first FDA approval of an MRD test as a companion diagnostic, the first Japanese PMDA approval for an MRD test, and European IVDR certification across more than 20 tumor types. A National Comprehensive Cancer Network (NCCN) Category 1 recommendation for bladder cancer further validated clinical adoption. Together, these milestones strengthened the investment narrative around oncology-led growth and international expansion, fueling the stock's re-rating.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a much larger ecosystem of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a streamlined view of strategies that are currently attracting attention. The bots vary in trading style, holding timeframe, and performance metrics, so investors can explore approaches aligned with their own objectives and risk tolerance. For those interested in systematic, data-driven trading tools, the Trending AI Robots page offers a practical starting point to review active strategies across the market.
NTRA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on continued Signatera volume growth and pricing trends, including pending MolDX coverage decisions that management has estimated could add $150 million to $200 million to the test's average selling price over time. Progress toward the roughly $2,000 long-term ASP target and execution of the Japanese commercial launch remain key milestones.
Quarterly earnings and guidance updates will be closely watched, as will data readouts from large prospective trials and any additional regulatory or guideline inclusions. Risks include competition in oncology and prenatal testing from rivals such as EXAS and GH, potential reimbursement tightening, and the elevated valuation the stock now carries. Macroeconomic factors affecting healthcare spending and diagnostic reimbursement could also influence sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NTRA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NTRA turned positive on September 17, 2026. Looking at past instances where NTRA's MACD turned positive, the stock continued to rise in 45 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on NTRA as a result. In 87 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +5.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 241 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 239 of 282 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.573) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties